Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
CoTec Holdings Corp. Files Third Quarter Financial Statements and MD&A and Provides Market Commentary
Premier American Uranium Completes US$5 Million Strategic Equity Investment by DISA Uranium; IsoEnergy Increases its Strategic Holding
